Amplia Therapeutics Limited, a pharmaceutical company, is currently working on developing FAK inhibitors for cancer and fibrosis. The lead molecule, AMP945, is a highly specific inhibitor. The company has a strong pipeline for cancer and fibrosis research with a focus on FAK inhibitors. Amplia Therapeutics Limited is making significant strides in the world of pharmaceuticals, and they intend to continue to develop innovative treatments aimed at improving patient outcomes.
Amplia Therapeutics's ticker is ATX
The company's shares trade on the ASX stock exchange
They are based in Melbourne, Australia
There are 1-10 employees working at Amplia Therapeutics
It is http://www.ampliatx.com
Amplia Therapeutics is in the Healthcare sector
Amplia Therapeutics is in the Biotechnology industry
The following five companies are Amplia Therapeutics's industry peers: